Want to see IN:SAKAR full AI Analyst Report?
Top Page
Sakar Healthcare Ltd
(SAKAR)
Select Model
Select Model
Rating:66Neutral
Price Target:
₹1,048.00
▲(30.64% Upside)
Action:Reiterated
Date:10/27/26
The score is driven primarily by improving financial performance—strong growth, healthy profitability, and a significantly strengthened balance sheet—partly offset by still-unproven cash flow consistency. Technicals are neutral-to-weak in the near term, and the high P/E meaningfully reduces the overall score due to valuation risk.
Positive Factors
Accelerating Revenue Growth
Accelerating revenue growth indicates stronger product demand and expanding commercial scale across Sakar’s pharmaceutical formulation portfolio. If sustained, this growth can improve operating leverage, support investment in additional products and markets, and strengthen the company’s competitive position.
Negative Factors
Thin Cash Conversion
Cash generation has improved, but free cash flow remains modest relative to reported earnings and follows several years of negative free cash flow. This weakens earnings quality and means Sakar’s ability to fund expansion internally still depends on proving that positive cash generation is durable.
Read all positive and negative factors
Positive Factors
Negative Factors
Accelerating Revenue Growth
Accelerating revenue growth indicates stronger product demand and expanding commercial scale across Sakar’s pharmaceutical formulation portfolio. If sustained, this growth can improve operating leverage, support investment in additional products and markets, and strengthen the company’s competitive position.
Read all positive factors
Sakar Healthcare Ltd (SAKAR) vs. iShares MSCI India ETF (INDA)
Market Cap
₹20.74B
Dividend YieldN/A
Average Volume (3M)144.99K
Price to Earnings (P/E)49.0
Beta (1Y)0.61
Revenue Growth47.99%
EPS Growth117.99%
CountryIN
Employees435
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)19.27
Shares Outstanding21,949,910
10 Day Avg. Volume194,460
30 Day Avg. Volume144,990
Financial Highlights & Ratios
PEG Ratio0.52
Price to Book (P/B)3.42
Price to Sales (P/S)4.41
P/FCF Ratio100.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Sakar Healthcare Ltd Business Overview & Revenue Model
Company Description
Sakar Healthcare Limited, founded in 2004 and based in Ahmedabad, India, is a pharmaceutical company actively involved in the full spectrum of drug development, from research and manufacturing to marketing its products. The company's diverse produ...
How the Company Makes Money
Sakar Healthcare primarily makes money by selling pharmaceutical formulations (finished-dosage products). Revenue is generated through (1) domestic sales of its branded/generic formulations to distributors, wholesalers, hospitals, pharmacies, and ...
Sakar Healthcare Ltd Financial Statement Overview
Summary
Income Statement
82
Very Positive
Balance Sheet
86
Very Positive
Cash Flow
58
Neutral
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.02B | 2.52B | 1.78B | 1.54B | 1.33B | 1.28B |
| Gross Profit | 880.97M | 661.78M | 427.91M | 699.59M | 598.12M | 534.12M |
| EBITDA | 844.99M | 711.76M | 509.44M | 394.24M | 378.12M | 315.72M |
| Net Income | 428.65M | 304.85M | 175.02M | 116.71M | 127.59M | 152.43M |
Balance Sheet | ||||||
| Total Assets | 5.16B | 4.81B | 4.15B | 3.89B | 3.36B | 2.68B |
| Cash, Cash Equivalents and Short-Term Investments | 2.65M | 2.60M | 3.09M | 4.66M | 35.23M | 71.36M |
| Total Debt | 130.10M | 553.04M | 749.55M | 793.52M | 1.19B | 928.62M |
| Total Liabilities | 1.70B | 1.57B | 1.30B | 1.26B | 1.63B | 1.40B |
| Stockholders Equity | 3.46B | 3.24B | 2.85B | 2.62B | 1.73B | 1.27B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 110.19M | -135.52M | -350.93M | -468.81M | -618.33M |
| Operating Cash Flow | 0.00 | 393.71M | 187.31M | 244.67M | 353.14M | 356.99M |
| Investing Cash Flow | 0.00 | -283.52M | -307.09M | -515.39M | -743.77M | -903.72M |
| Financing Cash Flow | 0.00 | -110.68M | -34.79M | 274.45M | 410.96M | 320.33M |
Sakar Healthcare Ltd Technical Analysis
Neutral
802.20
Price Trends
1016.09
Negative
935.90
Positive
744.93
Positive
Market Momentum
-27.01
Positive
45.53
Neutral
62.86
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:SAKAR, the sentiment is Neutral. The current price of 802.2 is below the 20-day moving average (MA) of 976.02, below the 50-day MA of 1016.09, and above the 200-day MA of 744.93, indicating a neutral trend. The MACD of -27.01 indicates Positive momentum. The RSI at 45.53 is Neutral, neither overbought nor oversold. The STOCH value of 62.86 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:SAKAR.
Sakar Healthcare Ltd Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | ₹14.33B | 31.87 | ― | 1.65% | 11.71% | -26.92% | |
74 Outperform | ₹16.46B | 13.61 | ― | 0.82% | 20.22% | 73.03% | |
73 Outperform | ₹18.09B | 21.14 | ― | 0.52% | 0.44% | 48.60% | |
70 Outperform | ₹10.05B | 10.37 | ― | 0.36% | 10.20% | 11.70% | |
66 Neutral | ₹20.74B | 49.03 | ― | ― | 47.99% | 117.99% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
51 Neutral | ₹31.95B | 53.99 | ― | 1.14% | 66.39% | -72.31% |
* General Sector Average
IN:SAKAR
Sakar Healthcare Ltd
944.80
572.70
153.91%
IN:INDSWFTLAB
Ind-Swift Laboratories Ltd.
367.40
265.25
259.67%
IN:JAGSNPHARM
Jagsonpal Pharmaceuticals Ltd.
216.90
-5.32
-2.40%
IN:LINCOLN
Lincoln Pharmaceuticals Ltd
501.95
-29.59
-5.57%
IN:SYNCOMF
Syncom Formulation (India) Ltd.
19.25
2.69
16.26%
IN:VENUSREM
Venus Remedies Limited
1,231.75
791.09
179.52%
Sakar Healthcare Ltd Corporate Events
Sakar Healthcare Publishes Q1 FY27 Earnings Call Transcript
Aug 3, 2026
Sakar Healthcare Ltd has released the transcript of its Q1 FY27 earnings conference call, detailing discussions on its unaudited consolidated and standalone financial results for the quarter ended 30 June 2026. The document, filed with the Nationa...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.